Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis

Moga, Lucile; Laroyenne, Alexia; Larrue, Hélène; Bureau, Christophe; Rautou, Pierre‐Emmanuel

doi:10.1016/j.jhep.2020.10.011

Cited by 10 publications

(8 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prospective study of 292 subjects with NAFLD showed that 17% of the subjects who did not have cirrhosis were found to have portal hypertension (HVPG >5 mmHg), in which 0.5% of the subjects had CSPH. 11 Another observational study of 354 subjects with NAFLD also demonstrated similar findings, showing that 12 out of 100 subjects with portal hypertension (only based on clinical manifestation) did not exhibit any advanced fibrosis or cirrhosis. The authors also pointed out that the only significant difference between subjects with and without portal hypertension was the severity of steatosis.…”

Section: Clinically Significant Portal Hypertension In Non-alcoholic Fatty Liver Diseasementioning

confidence: 67%

“…The study also showed that liver stiffness measurement was markedly lower in portal hypertension without cirrhosis, while the ratio between spleen stiffness measurement and liver stiffness measurement was markedly higher in portal hypertension without cirrhosis. 15 In addition, MR-based methods have been well-correlated with a wide range of HVPG measurements (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). A study by Gharib et al 16 demonstrated an independent significant correlation (p=0.015) between HVPG and MRE of the liver, with a median HVPG of 6 mmHg from 23 subjects.…”

Section: Assessment Of Portal Hypertension In Non-alcoholic Fatty Liver Disease Without Cirrhosismentioning

confidence: 97%

See 1 more Smart Citation

Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment

Lesmana

Paramitha

Hasan

et al. 2021

EMJ

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is one of the emerging global health problems due to an increase of burden worldwide. It has been known that NAFLD is strongly associated with metabolic syndrome. The progression of NAFLD is a complex and multifactorial mechanism. Portal hypertension is still the main key in liver disease progression management. In NAFLD, portal hypertension might occur in the non-cirrhotic condition. Hepatic vein pressure gradient measurement has been considered as the gold standard for portal pressure assessment; however, due to its invasiveness and the need for a high-expertise centre, it is considered a non-practical measurement tool in clinical practice. Many other non-invasive parameters have been developed to replace the invasive measurement; however, there are still some limitations with regard to the technical issue, patient’s condition, and its accuracy in the different stages of the disease. Therefore, the authors review portal hypertension related to the clinical course of NAFLD, and the development of portal pressure evaluation in patients with NAFLD.

show abstract

Section: Clinically Significant Portal Hypertension In Non-alcoholic Fatty Liver Diseasementioning

confidence: 67%

Section: Assessment Of Portal Hypertension In Non-alcoholic Fatty Liver Disease Without Cirrhosismentioning

confidence: 97%

Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment

Lesmana

Paramitha

Hasan

et al. 2021

EMJ

View full text Add to dashboard Cite

show abstract

“…has not been established. 28,33,34 36 Fibrogenesis in NAFLD, which predominantly occurs at the central area of the liver lobule might be associated with the lower portal pressure and consequent milder splenomegaly compared to that of CLD-C. 20,22 Similarly, the portalpredominant fibrosis in CLD-C accounted for the higher portal pressure and higher ratio of spleen stiffness (SS) to LS of transient elastography in CLD-C patients than in alcohol-related liver disease patients. 37 However, there have been few studies comparing SS and LS between NAFLD patients and CLD-C patients.…”

Section: Discussionmentioning

confidence: 99%

“…reported that splenomegaly grades did not differ between NAFLD and CLD‐C patients with similar liver fibrosis grades, the present study revealed that NAFLD patients had a significantly smaller spleen volume than CLD‐C patients at F3. A recent study regarding hepatic venous pressure gradient measurements of NAFLD patients has reported that clinically significant portal hypertension is rare in NAFLD patients without cirrhosis 36 . Fibrogenesis in NAFLD, which predominantly occurs at the central area of the liver lobule might be associated with the lower portal pressure and consequent milder splenomegaly compared to that of CLD‐C 20,22 .…”

Section: Discussionmentioning

confidence: 99%

Comparison of thrombocytopenia between patients with non‐alcoholic fatty liver disease and those with hepatitis C virus‐related chronic liver disease

Kinoshita

Shima

Terasaki

et al. 2022

Hepatology Research

View full text Add to dashboard Cite

Aim Thrombocytopenia is widely recognized as a simple surrogate marker of liver fibrosis in non‐alcoholic fatty liver disease (NAFLD). Thrombocytopenia of NAFLD has not been compared with that of hepatitis C virus‐related chronic liver disease (CLD‐C). Here, we examined whether there is any difference in the platelet counts between patients with NAFLD and CLD‐C and investigated the underlying mechanisms. Methods A total of 760 biopsy‐confirmed NAFLD and 1171 CLD‐C patients were enrolled. After stratification according to the liver fibrosis stage, platelet counts between NAFLD and CLD‐C patients were compared. The platelet count, spleen size, serum albumin level, serum thrombopoietin level, and immature platelet fraction (IPF) value were also compared after covariate adjustment using propensity score (PS) matching. Results The median platelet counts (×104/μL) of NAFLD and CLD‐C patients were 20.2 and 18.7 (p = 2.4 × 10−5) in F1; 20.0 and 14.5 (p = 2.1 × 10−12) in F2; 16.9 and 12.3 (p = 8.1 × 10−10) in F3; and 11.1 and 8.1 (p = 0.02) in F4, respectively. In the F3 group, NAFLD patients had a significantly higher platelet count and significantly smaller spleen volume than CLD‐C patients. Although the serum thrombopoietin levels were comparable between NAFLD and CLD‐C patients, the IPF value of NAFLD patients was significantly higher than that of CLD‐C patients. Conclusions NAFLD patients had a significantly higher platelet count than CLD‐C patients following stratification according to the liver fibrosis stage. The milder hypersplenism and higher platelet production in NAFLD than CLD‐C may have contributed to this difference.

show abstract

“…Nonetheless, several studies have suggested that PH can be present in the early stages of NASH, when fibrosis is far less advanced or even absent. [2] , [3] , [4] , [5] , [6] , [7] , [8] …”

mentioning

confidence: 99%

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report

et al. 2023

View full text Add to dashboard Cite

Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis

Abstract: transport kinetics of the conjugated bile acid tracer 11 C-CSar quantified in healthy humans and patients by Positron Emission Tomography (PET).

Cited by 10 publications

References 2 publications

Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment

Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment

Comparison of thrombocytopenia between patients with non‐alcoholic fatty liver disease and those with hepatitis C virus‐related chronic liver disease

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report

Contact Info

Product

Resources

About